English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 15.36%
Price change 2019 → 2020: 63.41%
Price change 2020 → 2021: 49.25%
Price change 2021 → 2022: -58.50%
Price change 2022 → 2023: -62.75%
Price change 2023 → 2024: -15.90%
Price change 2024 → 2025: -38.14%
Price change 2025 → 2026: -65.05%
Price change 2026 (year to date): -65.41%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.93
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.98
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 79.37% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="DARE" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Daré Bioscience, Inc. | – | 0.93 | +9.1 % | 🔒 |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Femasys Inc. | – | 0.80 | +16.2 % | – |
| Geratherm Medical AG | – | 0.13 | −1.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Dare Bioscience, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2014 | 80,000 | -23.3 m | -29,177.5 % | n/a |
| 2016 | 766,000 | -39.3 m | -5,131.2 % | +857.5 % |
| 2022 | 10.0 m | -30.9 m | -309.5 % | +1,205.5 % |
| 2023 | 2.8 m | -30.2 m | -1,074.2 % | -71.9 % |
| 2024 | 9,784 | -4.1 m | -41,430.9 % | -99.7 % |
| 2025 | 1.0 m | -13.4 m | -1,300.7 % | +10,429.4 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Dare Bioscience, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 51.7 m | 34.7 m | 10.5 m | 15.7 m | 24.7 m |
| Total Debt | 270,546 | 488,737 | 1.4 m | 1.3 m | 2.7 m |
| Net Debt | -51.4 m | -34.2 m | -9.1 m | -14.4 m | -22.1 m |
| Equity | 38.8 m | 11.1 m | -5.0 m | -6.0 m | 2.8 m |
| Total assets | 55.8 m | 43.8 m | 21.3 m | 22.1 m | 32.5 m |
| Operating cash flow | -28.8 m | -18.1 m | -38.9 m | 5.4 m | -9.9 m |
| Investments (capex) | 14,524 | 63,069 | 629,430 | 573,046 | 385,278 |
| Free cash-flow | -28.8 m | -18.2 m | -39.5 m | 4.8 m | -10.3 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Dare Bioscience, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 11 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Dare Bioscience, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 12/11/2026. Expected EPS: -0.13.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Dare Bioscience, Inc.
What is the Dare Bioscience, Inc. share price?
Latest recorded price: 0.639 USD on 06/11/2026, for a market cap of 9.6 m USD.
What is the revenue of Dare Bioscience, Inc.?
1.0 m USD for fiscal year 2025, with net income of -13.4 m USD (net margin -1,300.7 %).
When does Dare Bioscience, Inc. report its next earnings?
The next release is expected on 12/11/2026. EPS expected by analysts: -0.13.
What do analysts say about Dare Bioscience, Inc.?
Out of 6 analysts: 6 buy or strong buy, 0 hold, 0 sell or strong sell.
Is Dare Bioscience, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US23666P2002).
How many employees does Dare Bioscience, Inc. have?
21 full-time employees according to the latest published profile.
Who runs Dare Bioscience, Inc.?
Sabrina Martucci Johnson is the company's chief executive.